Xinlitai plans to apply for 10 clinical approvals (including 3 biological drugs) this year
-
Last Update: 2015-03-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Kevin sing ye, general manager of xinlitai, disclosed to investors that in 2015, the company plans to apply for clinical approval documents for 10 new products (including 3 in the field of Biopharmaceutics) Shenyin Wanguo research report said that in November 2014, it acquired the famous biomedical R & D and industrialization companies in the industry, Suzhou Jinmeng and Chengdu Jinkai The target company has more than ten biomedical products in reserve The product recombinant human parathyroid hormone 1-34 freeze-dried powder needle with the fastest R & D progress is in phase III clinical practice In time, the merger and acquisition cases of alishatan, Jinmeng and Jinkai are expected to grow into large profit volume businesses.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
